Cargando…
Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study
Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular residual disease (MRD) detection in lung cancer. As the next‐generation sequencing standardized panel for ctDNA detection emerges, its clinical utility needs to be validated. We prospectively recruited 184 resectable...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158775/ https://www.ncbi.nlm.nih.gov/pubmed/36732646 http://dx.doi.org/10.1002/1878-0261.13387 |